Kazia

Kazia Therapeutics (ASX:1AD)

Kazia, a cancer drug developer, is in Phase 2 with GDC-0084, a PI3K inhibitor for the treatment of glioblastoma originally developed by Genentech. In addition to GDC-0084, Kazia has an ovarian cancer drug (developed internally) that completes Phase 1 in 2018.